Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Metabolon Collaborates with GSK for Metabolomics Research Platform

By BiotechDaily International staff writers
Posted on 02 Jun 2014
Metabolon, Inc. (Research Triangle Park, NC, USA), a diagnostics and research services company offering metabolomics research platforms, has entered into a collaboration with GlaxoSmithKline (GSK; London, UK) to provide metabolomic profiling services and to collaborate on other research projects utilizing Metabolon’s DiscoveryHD4 platform.

The collaboration will give GSK access to Metabolon’s bioinformatics tools in addition to the company’s proprietary disease ontologies, as well as visualization tools that will integrate metabolomics data with existing genomics and proteomics data.

John Ryals, Metabolon president and CEO, commented, “We are pleased to announce a collaboration with GSK. We believe that embedding metabolomic profiling capabilities at the various stages of R&D is important to enhance the phenotypic ‘picture’ with the aim of yielding translatable, meaningful results. Gaps of knowledge can be bridged through the understanding metabolomics provides, which could lead to better targets, higher quality molecules, faster time to the clinic, and reduced risk and cost.”

Metabolomics has conducted thousands of metabolomics studies across numerous therapeutic areas and has developed expertise in metabolic pathways and targets that are involved in the onset of disease and its progression. Metabolon’s technology platforms are known for their rapid, repeatable results. Expert, credentialed biochemists interpret biologic data to provide actionable understanding into key disease metabolic processes, drug action, and patient response.

Metabolomics is a rapidly evolving field of biochemical research and discovery focused on the measurement of small molecules involved in metabolism. Metabolon’s proprietary metabolomics technology maps these small molecule pathways to identify diseases, discover biomarkers, and better understand complex biologic processes. The company’s business uses its metabolomics technology to conduct sponsored studies for life sciences researchers in industry and academia, which provide clues into complex biochemical processes. Data from these studies are used to populate Metabolon’s large and growing metabolomic information and pathway knowledge databases, which generate new product concepts for the company’s diagnostics business.

Related Links:

Metabolon
GlaxoSmithKline



Channels

Genomics/Proteomics

view channel
Image: Pluristem technicians produce PLacental eXpanded (PLX) cells in the company\'s state-of-the-art facility (Photo courtesy of Pluristem Therapeutics).

Placental Cells Secrete Factors That Protect Nerves from Ischemic Damage

Cells derived from placenta have been found to protect PC12 cells—rat-derived cells that behave similarly to and are used as stand-ins to study human nerve cells—in a culture-based ischemic stroke model.... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.